A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms LenCombo
- Sponsors Sanofi
- 10 May 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 10 May 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 23 Nov 2018 Planned End Date changed from 28 Dec 2018 to 1 Jun 2019.